HFR is pleased to announce that it has been re-issued a Certificate of GMP Compliance for active substances intended for clinical trials, following a successful on-site inspection by the Medicines and Healthcare products Regulatory Agency (MHRA) on 17 September 2025.
This latest certification reinforces the company’s long-standing commitment to the highest standards of quality, regulatory compliance, and operational excellence across its development and manufacturing activities.
HFR has maintained GMP approval since 2007, consistently demonstrating its ability to meet the stringent requirements expected for the manufacture of active pharmaceutical ingredients supporting clinical research.
The outcome of the MHRA inspection reflects the professionalism, expertise, and dedication of the HFR team, whose efforts ensure the delivery of reliable, compliant, and high-quality manufacturing services to partners across the life sciences sector.
This re-certification further strengthens HFR’s position as a trusted partner for GMP manufacturing, supporting clients in progressing innovative therapies from development through to clinical trials.
Ready for smarter chemistry solutions that scale success?
Work with our expert chemists to accelerate research, development, and manufacturing. Gain clarity, confidence, and momentum across every stage.
